Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Date:6/3/2008

oth daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocellular carcinoma, soft tissue sarcoma, GIST tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Disease stabilization, defined as time on treatment without progression for at least 6 months has been seen in 20 tumor types, including metastatic renal cell cancer, hepatocellular carcinoma, melanoma, carcinoid, prostate, head and neck, breast, and small cell lung cancer. Responding patients, including stable disease, have been treated for various durations up to more than three years.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015 Noting the need to ... policies currently practiced by the rapidly consolidating pharmacy benefit ... today praised Ohio Governor ... new state effort to help pull back the curtain ... "We applaud Governor Kasich for bringing badly-needed reform ...
(Date:7/7/2015)... 7, 2015  Dedicated to promoting wellness and giving ... took the purple pledge in support of Alzheimer,s ... Brain-Awareness Month, a time to shine a purple light ... all the people in our community who are affected ... the disease, and helps mobilize friends, family members, neighbors ...
(Date:7/7/2015)... and BANGALORE , July ... a global technology provider of innovative clinical trial data ... (Industry Standard Research Reports) recent publication named " EDC ... Performance (2015) ". ISR Reports is one of the ... industry, and this report evaluated 22 EDC and eCOA ...
Breaking Medicine Technology:National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 2National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 3Purple for a Purpose: Supporting Alzheimer's & Brain-Awareness Month 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
... D-Pharm announced today the,completion of a financial round, which ... late stage clinical stroke program. The,financial round combined a rights ... of NIS 28 million. The IPO was oversubscribed and the,unit ... minimum price. The,company,s pre-money valuation was NIS 120 million. , ...
... , , , ... Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a ... patients manage this devastating disease. , , Extavia ... MS to reduce the frequency of clinical exacerbations. The therapy is also ...
Cached Medicine Technology:D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE) 2D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE) 3US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 2US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 3US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 5US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 6US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 7
(Date:7/7/2015)... ... July 07, 2015 , ... Seattle-based ... have merged to form Camber Collective. Camber Collective provides strategic advisory services ... SwitchPoint’s strategy consulting expertise with Hope Consulting’s deep experience in customer insights, ...
(Date:7/7/2015)... IL (PRWEB) , ... July 07, 2015 , ... ... the only industry group whose board is limited to permit holders. The Medical ... on how to move the industry forward and are committed to making sure ...
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time ... so Amica Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator ... Leisure activities/sports, , Start slowly. Going from no activity to ...
(Date:7/7/2015)... ... 07, 2015 , ... On June 22nd-26th, 2015, the Cobo ... National Baptist Convention 110th Annual Session of the National Baptist Congress of Christian ... churches and their congregations, medical professionals and health-related organizations, this week long event ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... creative design firm, today announced that TimberNook ( http://www.timbernook.com/ ) has ... campaign, content strategy, and marketing launch package for new camp providers. TimberNook ...
Breaking Medicine News(10 mins):Health News:SwitchPoint and Hope Consulting Have Merged to Form Camber Collective 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 2Health News:A Forever Recovery CEO Per Wickstrom Speaks to Audience at National Baptist Convention's 11th Annual Health Fair 3Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2
... 2 Diabetes and High LDL- ... Cholesterol ... ACE/AACE Road Maps, PARSIPPANY, N.J., May 16 Daiichi Sankyo, Inc. (DSI),announced ... combination with metformin- or,sulfonylurea- based therapy, significantly lowers blood glucose (as,measured by A1C) ...
... Patients who feel better live longer, say Mayo Clinic researchers, ... study results released May 15 as part of the 44th ... , Mayo Clinic cancer researcher and the studys lead ... is an independent factor in survival. , Quality of life ...
... tool could allow physicians to determine much sooner if ... -- A simple blood test to check levels of ... how well treatments are working in women with metastatic ... study. , "It can take several weeks, and ...
... HAE: TSX, MONTREAL, May 16 /PRNewswire-FirstCall/ - ... human,proteins for commercialization, announced today that its Chairman ... will present at the,upcoming Rodman & Renshaw 5th ... in the Zephyr Room at Le Meridien Beach ...
... Inc. (Nasdaq: JAZZ ) announced today that Robert ... at two,upcoming investor conferences., Mr. Myers will speak ... London at 9:30 a.m. BST (4:30 a.m. EDT) on,Wednesday, ... Mr. Myers will present at the FBR Capital,Markets Spring ...
... INDIANAPOLIS, May 15 Lung cancer patients,whose histology is ... according to data from a pivotal non-small cell lung ... Eli Lilly and Company,s,ALIMTA(R) (pemetrexed for injection), will be ... of Clinical Oncology (ASCO) in Chicago,Ill., May 30 -- ...
Cached Medicine News:Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News:Cancer patients' quality of life directly relates to their survival 2Health News:Cancer patients' quality of life directly relates to their survival 3Health News:Blood Test Helps Docs Assess Breast Cancer Treatment 2Health News:Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7
19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Angled, 20 gauge x 25 mm cannula with 30 gauge x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub, angled 45 degrees 2.5 mm from tip. 10 per box....
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Includes one aluminum Fox eye shield and one eye Garter shield cover. Packaged 50 per box. White only....
Medicine Products: